01—Abstract
Summary
Summary of the 8-K filed April 26, 2024. Cited figures are marked; the original filing is the authoritative source.
On April 25, 2024, Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders, at which 115,681,780 of the 127,054,240 shares of common stock outstanding as of the record date were represented.
Stockholders elected two Class II directors, Barbara Duncan and Mahesh Krishnan, M.D., to three-year terms expiring at the 2027 Annual Meeting. Duncan received 90,120,424 votes for and 15,016,536 against, while Krishnan received 103,968,663 votes for and 1,164,017 against. Dr. Krishnan was subsequently appointed by the Board to the Nominating and Corporate Governance Committee.
Stockholders also approved three other proposals: an advisory vote on named executive officer compensation (102,860,435 for, 2,190,603 against), an amendment to the Amended and Restated Certificate of Incorporation reflecting Delaware law provisions on officer exculpation (91,512,252 for, 13,612,616 against), and the ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 (114,912,469 for, 647,868 against). The exculpation amendment became effective upon filing the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on April 25, 2024, a copy of which is filed as Exhibit 3.1. The filing is a routine governance disclosure.
It reports the results of shareholder votes and a charter amendment, and it contains no financial results, guidance, or transaction disclosures. Details of each proposal are described in the company's definitive proxy statement filed March 15, 2024.
02—Key points
Key Highlights
- Annual Meeting held April 25, 2024, with 115,681,780 of 127,054,240 outstanding shares represented (about 91% participation by the reported counts)
- Barbara Duncan and Mahesh Krishnan, M.D. elected as Class II directors with terms expiring at the 2027 Annual Meeting
- Advisory say-on-pay proposal approved, with 102,860,435 votes for and 2,190,603 against
- Certificate of Incorporation amendment on Delaware officer exculpation approved and effective April 25, 2024, with 91,512,252 votes for and 13,612,616 against
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal 2024 with 114,912,469 votes for
- Dr. Krishnan appointed to the Nominating and Corporate Governance Committee of the Board
- Filing contains no financial results, guidance, or material transactions; it is a routine governance update
03—Questions
Frequently Asked Questions
Who was elected to the board at the April 2024 annual meeting?
Barbara Duncan and Mahesh Krishnan, M.D. were elected as Class II directors for three-year terms expiring at the 2027 Annual Meeting. Duncan received 90,120,424 votes for and 15,016,536 against, and Krishnan received 103,968,663 votes for and 1,164,017 against.
Did shareholders approve executive compensation?
Yes. In the advisory vote on named executive officer compensation, 102,860,435 votes were cast for, 2,190,603 against, and 247,626 abstained, with 10,383,116 broker non-votes. The proposal was approved.
What changed in the company's charter?
Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation. The company filed the amended charter with the Delaware Secretary of State on April 25, 2024, and it became effective at that time. A copy is filed as Exhibit 3.1.
Who is the company's independent auditor for 2024?
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 114,912,469 votes for, 647,868 against, and 121,443 abstentions.
04—Continue